Cic edizioni internazionali
Functional Neurology

Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal

Review, 7 - 18
doi: 10.11138/FNeur/2018.33.1.007
Tag this article
Abstract
Enhanced HTML Full text PDF
Three different type A botulinum neurotoxins (BoNTAs) — onabotulinumtoxinA, abobotulinumtoxinA and incobotulinumtoxinA) — are currently marketed in Europe to treat several conditions. Differences between BoNTA preparations, which depend on their
specific biotypes and manufacturing processes, lead to clinically relevant pharmacotherapeutic dissimilarities.
All three available products are separately recognized and reviewed in American Academy of Neurology guidelines. The neurotoxin load/100U is likewise different among the different BoNTAs, with the result that the specific potency of the 150kD BoNTA neurotoxin is calculated as 137 units/ng for onabotulinumtoxinA, 154 units/ng for abobotulinumtoxinA, and 227 units/ng for incobotulinumtoxinA. It is important for clinicians to have all three BoNTAs available in order to choose the most suitable preparation for the specific indication in the single patient. Commercially available BoNTAs must be recognized as different from one another, and therefore as non-interchangeable.
The essential experience of the clinician is of the utmost importance in choosing the most appropriate treatment.

Vol. XXXIII (No. 4) 2018 October/December

  1. Music and neurorehabilitation: Yes, we can!
    Raglio A.
    doi: 10.11138/FNeur/2018.33.4.173
  2. Clinical and neuroimaging spectrum of hyperglycemia-associated chorea-ballism: systematic review and exploratory analysis of case reports
    Gómez-Ochoa S.A., Espín-Chico B.B., Pinilla-Monsalve G.D., Kaas B.M., Téllez-Mosquera L.E.
    doi: 10.11138/FNeur/2018.33.4.175
  3. Recovery of circadian melatonin rhythm after a melatonin holiday in daytime haemodialysis patients on long-term exogenous melatonin
    Sparla S., Koch B.C., Bosma R., Nagtegaal E.
    doi: 10.11138/FNeur/2018.33.4.188
  4. Multiple sclerosis and non-dystrophic myotonias: do they share a common pathophysiology?
    Portaro S., Naro A., Russo M., Bramanti P., Lauria P., D'Aleo G., La Rosa G., Bramanti A., Calabrò R.S.
    doi: 10.11138/FNeur/2018.33.4.194
  5. From paper to informatics: the Post Soft Care-App, an easy-to-use and fast tool to help therapists identify unmet needs in stroke patients
    De Bartolo D., Morone G., Lupo A., Aloise F., Baricich A., Di Francesco D., Calderone C., Cisari C., Verdecchia G., Sandrini G., Pistarini C., Antonucci G., Smania N., Paolucci S., Iosa M.
    doi: 10.11138/FNeur/2018.33.4.200
  6. Automated mechanical peripheral stimulation and postural control in subjects with Parkinson’s disease and freezing of gait: a randomized controlled trial
    Prusch J.S., Kleiner A.F.R., Salazar A.P., Pinto C., Marchese R.R., Galli M., Pagnussat A.S.
    doi: 10.11138/FNeur/2018.33.4.206
  7. Is bupropion useful in the treatment of post-stroke thalamic apathy? A case report and considerations
    Aragona B., De Luca R., Piccolo A., Le Cause M., Destro M., Casella C., Filoni S., Calabrò R.S.
    doi: 10.11138/FNeur/2018.33.4.213
  8. TIA patients with higher ABCD3-I scores are prone to a higher incidence of intracranial stenosis, unstable carotid plaques and multiple-vessel involvement
    Yu Q., Miao W., Han J.
    doi: 10.11138/FNeur/2018.33.4.217
  9. Is there a correlation between urological and cardiovascular dysfunction in Parkinson’s disease?
    Brusa L., Rocchi C., Ponzo V., Stanzione P., Finazzi E., Attanasio A.
    doi: 10.11138/FNeur/2018.33.4.225
  10. Cross-cultural adaptation and validation in the Italian population of the wolf motor function test in patients with stroke
    Berardi A., Dhrami L., Tofani M., Valente D., Sansoni J., Galeoto G.
    doi: 10.11138/FNeur/2018.33.4.229
  11. The dawn of algometry: Paolo Mantegazza’s research on pain
    Cani V.
    doi: 10.11138/FNeur/2018.33.4.254
Last Viewed articles: la lista degli ultimi x visitati.
  1. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal
    Ferrari A., Manca M., Tugnoli V., Alberto L.
    doi: 10.11138/FNeur/2018.33.1.007
credits